NutriBand Inc. (NASDAQ: NTRB)

NutriBand Inc. (NTRB) operates in the pharmaceutical industry, specializing in the development of transdermal pharmaceutical products. The company's main business activities revolve around creating a portfolio of transdermal products based on its proprietary AVERSA abuse deterrent transdermal technology. This technology aims to reduce the abuse and misuse of fentanyl patches, which are primarily used for treating chronic pain.

NutriBand's business model is geared towards developing and commercializing transdermal pharmaceutical products that address unmet medical needs. The company's products offer an alternative route of administration for treating conditions such as chronic pain, opioid use disorder, and attention deficit/hyperactivity disorder. The company's product pipeline includes AVERSA Fentanyl, as well as other products that utilize the AVERSA technology, such as AVERSA Buprenorphine and AVERSA Methylphenidate.

The company's lead product, AVERSA Fentanyl, is an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with the AVERSA abusedeterrent transdermal technology. This product aims to deter the abuse and accidental misuse of fentanyl patches by incorporating aversive agents into the patch that make abuse an unpleasant experience.

In the transdermal pharmaceutical market, NutriBand competes with companies such as Purdue Pharma, Teva Pharmaceuticals, and Johnson & Johnson. The company's competitive advantages include its proprietary AVERSA technology, which is designed to deter the abuse and misuse of fentanyl patches, and its focus on developing products that address unmet medical needs.

NutriBand's products are designed to be manufactured using contract manufacturers and, potentially, collaboration partners. The company plans to continue relying on contract manufacturers and potential collaboration partners to manufacture commercial quantities of its products, should they receive approval for marketing by the FDA.

The company's regulatory strategy is focused on obtaining FDA approval for its products through the 505(b)(2) NDA regulatory pathway. This pathway allows the company to reference the safety information on file at the FDA for the approved drug or to reference the published literature instead of having to generate new safety information that would typically be required for new chemical entities.

In terms of market assessment, NutriBand engaged Health Advances, a leading healthcare consulting company, to assess the market opportunity and commercial strategy for AVERSA Fentanyl and AVERSA Buprenorphine. According to the assessment, AVERSA Fentanyl has the potential to reach peak annual US sales of $80-200 million, while AVERSA Buprenorphine has the potential to reach peak annual US sales of $70-130 million.